Compare BOOM & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOOM | ATOS |
|---|---|---|
| Founded | 1965 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.4M | 100.8M |
| IPO Year | N/A | 2012 |
| Metric | BOOM | ATOS |
|---|---|---|
| Price | $6.22 | $0.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $8.50 | $6.33 |
| AVG Volume (30 Days) | 183.8K | ★ 1.0M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $618,683,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.46 | $0.55 |
| 52 Week High | $9.92 | $1.29 |
| Indicator | BOOM | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 40.73 |
| Support Level | $6.16 | $0.68 |
| Resistance Level | $6.85 | $0.99 |
| Average True Range (ATR) | 0.28 | 0.05 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 40.57 | 10.91 |
DMC Global Inc operates a diversified family of technical product and process businesses serving the energy, industrial and infrastructure markets. Its business is organized into three segments: Arcadia, DynaEnergetics, and NobelClad. Arcadia Products supplies architectural building products, including exterior and interior framing systems, windows, urtain walls, storefronts etc to the commercial construction market. NobelClad is involved in the production of explosion-welded clad metal plates for use in the construction of corrosion-resistant industrial processing equipment and specialized transition joints. DynaEnergetics driver, designs manufactures and distributes products utilized by the oil and gas industry principally for the perforation of oil and gas wells.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.